By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in insightful discussions and building meaningful connections with industry ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

A recent study found that several children were hospitalized after drinking slush ice drinks containing glycerol. Now, one mom is detailing her daughter’s hospitalization just minutes after consuming ...

"P-Sam is an exciting new ADC targeting B7-H4 ... unacceptable drug-related toxicity, or withdrawal of consent. Almost all patients in the study (94%) had received prior platinum chemotherapy ...

A resurgence of interest One reason that ADCs struggled to gain traction is due to their potential for toxicity. Mylotarg (gemtuzumab ozogamicin) is an ADC created by Pfizer and approved in 2000 ...

These assets are engineered to produce minimal off-target toxicity, with a higher therapeutic ... to swiftly advance our portfolio of promising ADC assets," said David Lennon, President and ...